在开始治疗阿片类药物使用障碍的布普伦诺芬治疗的个人中使用 gabapentin

相关实验视频

Updated: Jul 17, 2025

04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

383

Matthew S Ellis¹, Kevin Y Xu¹, Vitor S Tardelli^2,3

¹Department of Psychiatry, Washington University in St Louis, School of Medicine, St Louis, Missouri.

JAMA psychiatry

|September 6, 2023

概括

在阿片类药物使用障碍 (OUD) 治疗中非标签性 gabapentin 的使用是常见的,但与与药物相关的中毒风险增加无关. 需要进一步的研究来了解 gabapentin.

科学领域:

药理学和成医学药理学和成医学
临床研究临床研究
医疗保健服务研究医疗服务研究

背景情况:

在阿片类药物使用障碍 (OUD) 治疗中,加巴丁的处方增加了非标签性使用.
处方的目的是管理并发症和戒断症状,尽管证据有限.

研究的目的:

评估OUD治疗中非标签性 gabapentin 使用的原因和相关风险.
评估在OUD患者中 gabapentin 使用和与药物有关的中毒之间的关联.

主要方法:

具有交叉设计的回顾性,反复事件,病例控制研究.
使用了12-64岁的个人使用OUD和布普伦诺芬处方的行政索赔数据 (2006-2016).
分析了人日,重点关注 gabapentin 暴露和与药物相关的中毒结果.

主要成果:

加巴丁不太可能被处方给黑人或西班牙裔患者,更可能给女性和那些患有并发病的人.
在接受 gabapentin 的患者中,近三分之一的患者经历了布诺芬开始后与药物相关的中毒.
经过调整后的分析表明,加巴丁的使用与因药物中毒而住院治疗之间没有显著的关联.

结论:

在OUD治疗中,加巴丁经常被处方用于各种疾病.
尽管 gabapentin 用户中毒率较高,但调整后的数据表明,布普伦诺芬与药物相关的中毒风险没有增加.
需要对加巴丁在OUD设置中的安全性概况进行更多研究.

相关概念视频

01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

333

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

333

01:20

Antiepileptic Drugs: Potassium Channel Activators

210

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

210

01:25

Analgesia and Pain Management

654

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

654

01:22

Opioid Receptors: Overview

1.0K

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...

1.0K

01:14

CNS Depressants: Barbiturates and Benzodiazepines

314

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

314